CRC should be divided into MMR-D cases involving the serrated neoplasia pathway and MMR-P cases involving the adenoma–carcinoma sequence if LGR5 is used as a prognostic marker, and LGR5 should be evaluated by RNA in situ hybridization. The gene discussed is MRC1; the disease is carcinoma.